At a glance
- Originator Novartis
- Class Quinazolines; Small molecules
- Mechanism of Action Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Actinic keratosis
Most Recent Events
- 16 Jul 2010 Discontinued - Preclinical for Actinic keratosis in Austria (Topical)
- 18 Sep 2002 Preclinical trials in Actinic keratosis in Austria (Topical)